GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (LTS:0A9E) » Definitions » FFO per Share

CureVac NV (LTS:0A9E) FFO per Share


View and export this data going back to 2021. Start your Free Trial

What is CureVac NV FFO per Share?

FFO per Share only applies to REITs.


CureVac NV Business Description

Traded in Other Exchanges
Address
Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.